購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
B6-hNLRP3 Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
B6-hNLRP3 Mouse
製品名
B6-hNLRP3 Mouse
製品ID
C001616
系統名
C57BL/6NCya-Nlrp3tm1(hNLRP3)/Cya
背景情報
C57BL/6NCya
状況
このマウス系統を論文で使用する場合は、「B6-hNLRP3 Mouse(カタログ番号C001616)はサイアジェンから購入しました。」と引用してください。
HUGO-GT Humanized Models
Immune Target Humanized Mouse Models
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
HUGO-GT Humanized Models
Immune Target Humanized Mouse Models
基本情報
検証 Data
関連リソース
基本情報
遺伝子名
遺伝子別名
AII, AVP, FCU, MWS, FCAS, KEFH, CIAS1, FCAS1, NALP3, C1orf7, CLR1.1, DFNA34, PYPAF1, AGTAVPRL
NCBI ID
染色体
Chr 1
MGI ID
さらに
系統詳細
The Cryopyrin protein, encoded by the NOD-like receptor family pyrin domain-containing 3 (NLRP3) gene, is a core component of the inflammasome in the innate immune system. As a member of the NOD-like receptor (NLR) family, NLRP3 is predominantly expressed in leukocytes and chondrocytes. It participates in the host defense against damage and infection by recognizing pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) to activate immune responses [1]. In its inactive monomeric state, NLRP3 senses intracellular damage signals, such as abnormal protein aggregates and lipid accumulation. Upon activation, NLRP3 oligomerizes, adopting an active conformation and assembling into inflammasome complexes, subsequently activating Caspase-1 to drive the maturation and secretion of pro-inflammatory cytokines, including IL-1β and IL-18 [1-2]. Activated NLRP3 not only induces the release of inflammatory cytokines but also triggers lytic cell pyroptosis. The intracellular components released during pyroptosis can further amplify inflammatory signals, forming a positive feedback loop of autoinflammation. Moreover, IL-1β can exacerbate the inflammatory cascade by stimulating the production of inflammatory markers such as IL-6 and high-sensitivity C-reactive protein (hsCRP) [3-4]. Given NLRP3's upstream position relative to IL-1β/IL-18 and other inflammatory factors, targeting its activity can effectively block the self-reinforcing mechanism of chronic inflammation, providing a significant therapeutic strategy for inflammation-related diseases [5]. The potential therapeutic areas include Alzheimer’s disease, Parkinson’s disease (via neuroinflammation modulation), inflammatory bowel disease, metabolic dysfunction-associated steatohepatitis (MASH), gout, and obesity-related metabolic inflammation [6-7].
The B6-hNLRP3 mouse model was generated by replacing the mouse Nlrp3 genomic region (from the ATG start codon to downstream of the 3'UTR) with the human NLRP3 sequence (from upstream of the ATG start codon to downstream of the 3'UTR), enabling stable expression of human NLRP3 protein. The B6-hNLRP3 mouse is suitable for studying inflammatory mechanisms, autoimmune diseases, neurodegenerative diseases, and metabolic diseases. It also serves as an ideal tool for human NLRP3-targeted drug development and preclinical efficacy evaluation.
参考文献
Xu J, Núñez G. The NLRP3 inflammasome: activation and regulation. Trends Biochem Sci. 2023 Apr;48(4):331-344.
Moretti J, Blander JM. Increasing complexity of NLRP3 inflammasome regulation. J Leukoc Biol. 2021 Mar;109(3):561-571.
Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010 Feb;10(2):89-102.
Booshehri LM, Hoffman HM. CAPS and NLRP3. J Clin Immunol. 2019 Apr;39(3):277-286.
Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019 Aug;19(8):477-489.
Yao J, Sterling K, Wang Z, Zhang Y, Song W. The role of inflammasomes in human diseases and their potential as therapeutic targets. Signal Transduct Target Ther. 2024 Jan 5;9(1):10.
Ma Q. Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction. Pharmacol Rev. 2023 May;75(3):487-520.
系統作製戦略
The mouse Nlrp3 locus (ATG start codon to downstream of the 3'UTR) was replaced with the human NLRP3 sequence (upstream of ATG to downstream of the 3'UTR) via gene editing technology.

Figure 1. Gene editing strategy of B6-hNLRP3 mice.
適用分野
Studies of the immune system and inflammasome activation mechanisms;
Pathological mechanism analysis of cryopyrin-associated periodic syndromes (CAPS);
Development, screening, and preclinical pharmacodynamic evaluation of NLRP3-targeted drugs;
Neuroinflammation modulation research in neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease);
Exploration of mechanisms in metabolic diseases and autoimmune diseases.
検証 Data
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
